<DOC>
	<DOCNO>NCT02993614</DOCNO>
	<brief_summary>This comparative effectiveness study compare new user SGLT-2 inhibitor new user glucose lower drug regard hospitalization heart failure cause mortality respectively . The study carry base data six country : Unites States , United Kingdom , Germany , Sweden , Denmark Norway</brief_summary>
	<brief_title>Comparative Effectiveness Cardiovascular Outcomes New Users SGLT-2 Inhibitors</brief_title>
	<detailed_description>In September 2015 EMPA-REG trial present data positive effect empagliflozin , SGLT-2 inhibitor cardiovascular ( CV ) outcomes . This create need data class medicine affect CV event rate use clinical practice . The primary aim observational study compare risk hospitalization heart failure , patient type 2 diabetes mellitus ( T2DM ) new user SGLT-2 inhibitor versus active comparison group include patient T2DM new user glucose lower drug . A secondary aim compare all-cause mortality use similar method . Exploratory aims estimate incidence acute myocardial infarction atrial fibrillation treatment group . The study carry base data six country : United States ( US ) , United Kingdom ( UK ) , Germany , Sweden , Denmark Norway . In UK data Clinical Practice Research Datalink ( CPRD ) , The Health Improvement Network ( THIN ) ; use study , US Humedica , MarketScan ; Sweden DAISY database ; Norway DAPHNE database Denmark DAFFODIL database ; Germany ( `` Diabetes Patientenverlaufsdokumentation '' [ DPV ] ) Manitoba Centre Health Care Policy ( MCHP ) Canada . The Study Population consist new user SGLT-2i glucose lower drug respectively . These compare regard hospitalization heart failure all-cause mortality ( possible UK Nordic country ) follow-up period . In addition , acute myocardial infarction atrial fibrillation assess descriptively two group respectively . The study period range launch first SGLT-2i country ( November 2012 Nordics , Germany UK , March 2013 US ) end late available data data source . The incidence heart failure hospitalization cause mortality compare new user SGLT-2 inhibitor comparator arm use hazard ratio ( relative risk ) correspond 95 % confidence interval . The analysis perform use Cox proportional hazard model appropriate method . Matching propensity score use balance potential confounding covariates SGLT-2i group reference group ensure two group similar possible baseline.To achieve sufficient power , meta-analysis base DerSimonian-Laird random effect model applied integrate point estimate individual database analyse calculate overall weighted estimate correspond 95 % CI .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>New user receiving dispense prescription SGLT2i medication glucose lowering drug , oral well injectable , include fixeddose combination ( FDC ) product contain medication group T2DM diagnosis prior index date â‰¥ 18 year old index date &gt; 1 year data history database prior index date Patients T1DM diagnosis Patients gestational diabetes within 1 year index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>